Secondary prevention of atherosclerosis
Abstract
Atherosclerosis is responsible for the majority of deaths in the developped countries.
This disorder is the underlying cause of heart attacks, strokes and peripheral vascular
disease. Although the etioloy is unknown, progress has been made in identifying the risk
factors that predispose to it. Thus, a number of conditions are more frequent in the
atherosclerotic patients: Hypercholesterolemia, hypertension and cigarette smoking are
the most potent, but another conditions has been implicated, such as age, male gender,
farnily or personal history of cardiovascular disease, low HDL-Cholesterol, high lipoprotein
(a), diabetes, hyperinsulinemia, left ventricular hypertrophia, abdominal obesity,physical
inactivity, alcoholism, stress-type of personality, high fibrinogen levels , postrnenopausic
woman, use of oral contraceptiv or microalbuminuria. The regression or interruption of
progression of atherosclerotic lesions can be acomplished in humans, as has been demonstrated
in an important number of studies
Downloads
References
THOMPSON, SG., KIENAST, J., PYKE, S., ET AL: "Hemostatic factors and the risk of
myocardial infarction or sudden death in patients with angina pectoris". N Engl J Med
(1995), 332: 635-41.
BROWN, G., ALBERS, J. J., FISHER, L. D., et al: "Regression of coronary artery
disease as a result of intensive lipid-Iowering therapy in men with high levels of apolipoprotein
B" . N Engl J Med (1990), 323:1289-98.
LIPID RESEARCH CLINICS PROGRAM. "The Iipid research c1inics coronary primary
prevention trial results. 1. Reduction in incidence of coronary heart disease". JAMA 1984,
251:351-64.
MANNINEN, V., ELO, M. O., FRlCK, M. H., et al: "Lipid alterations and decline in tbe
incidence of coronary heart disease in the Helsinki Heart Study". JAMA (1988), 260:641-51.
ROUSSOUW, J. E.: "The effects of lowering serurn cholesterol on coronary heart disease
risk". Med Clin North Am (1994), 78: 181-95.
BANEGAS, J. R., RODRÍGUEZ ARTALEJO, F., DOMÍNGUEZ, V., REY CALERO, J.:
"How much benefit can be obtained from cardiovascular disease intervention programs".
Rev Epidem Sante Publ (1992), 40:313-322.
LEVINE, J. F., KEANEY, Jr. and VlTA. J. A.: "Medical progress: Cholesterol reduction
in cardiovascular disease-Clinical benefits and possible mechanism". N Engl J Med
(1995), 332: 512-21.
CORONARY DRUG PROJECT RESEARCH GROUP: "Clofibrate and niacin in coronary
heart disease". JAMA (1975), 231:360-81.
CARLSON, L. A., ROSENHAMER, G.: "Reduction of mortality in the Stockbolm
ischaerruc heart disease secondary prevention study by combined treatment with clofibrate
and nicotinic acid". Acta Med Scand (1988), 223:405-18.
BUCHWALD, H., VARCO, R. L., MATSS, J. P. et al.: "Effect of partial ileal bypass
surgery on mortality and morbidity from coronary heart disease in patients with
hypercholesterolemia: Reprt of the program on the surgical control of the hyperlipidemias
(POSCH)". N Engl J Med (1990), 323:946-55.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
